The North America Bispecific Antibodies Market would witness market growth of 39.6% CAGR during the forecast period (2023-2030).
Bispecific antibodies (BsAbs), which may bind to two separate antigens or two different epitopes on the same antigen, are developing to increase the specificity and potency of antibodies. Bispecific antibodies produce superior outcomes with fewer adverse effects during low-cost treatment. Bispecific antibody sales are predicted to increase due to their potential therapeutic benefit against multiple diseases simultaneously. These are used to treat various illnesses, including infectious diseases, cardiovascular diseases, allergies, ocular issues, autoimmune and inflammatory disorders, and organ transplant rejection.
Six BsAbs, including Catumaxomab, the first approved BsAb, have been given FDA and/or EMA approval for cancer immunotherapy as of 2022. Hundreds of additional BsAbs are undergoing research, and the market is anticipated to expand in the coming years. As a result, major pharmaceutical corporations are becoming increasingly interested in researching and funding this promising immunotherapy. Because of their efficacy in oncology, BsAbs are also being investigated for the treatment of uncommon diseases, ophthalmic disorders, infections, autoimmune disorders, and other diseases.
The rising prevalence of autoimmune disorders in Canada is also responsible for the growing demand for bispecific antibodies. 19.3% of Canadians who were 15 years of age or older reported having arthritis in 2017 (or around 5.7 million persons), according to Statistics Canada. The prevalence of this chronic illness was 16.0% in men and 22.4% in women. With an increasing emphasis on creating cutting-edge bispecific antibody platforms and technologies, Canada is another significant market for North American antibodies. Many academic institutions and biotechnology firms are engaged in the research and development of bispecific antibody medicines in the nation. Therefore, the region presents lucrative growth potential for the market.
The US market dominated the North America Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $26,163.4 million by 2030. The Canada market is exhibiting a CAGR of 42.7% during (2023 - 2030). Additionally, The Mexico market would showcase a CAGR of 41.5% during (2023 - 2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Bispecific Antibodies Market is Projected to reach USD 80.2 Billion by 2030, at a CAGR of 40.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
By Indication
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 